GENELUX CORPORATION - COMMON STOCK

3.9600

24-January-25 16:45:00

15 minutes delayed

Stocks

+0.6000

+17.86%

Today's range

3.2500 - 4.1597

ISIN

N/A

Source

NASDAQ

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

29 Jun 2023 07:00:00 By Nasdaq GlobeNewswire
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

22 Jun 2023 07:00:00 By Nasdaq GlobeNewswire
Genelux Corporation Announces $18 Million Private Placement

12 Jun 2023 07:00:00 By Nasdaq GlobeNewswire
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology

25 May 2023 16:01:00 By Nasdaq GlobeNewswire
Genelux Corporation Announces $33 Million Private Placement

15 May 2023 07:00:00 By Nasdaq GlobeNewswire
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

23 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.